Table Of Content

Author index A Binder,C . 898 Chantelau,E. 191 Duner,E . 129 Bindra,D.S. 224 Chantres, M.T. 583 Dunger, D.B. 542 Aanstoot, H.J. 436 Bingley, P.J. 32 Chatelain, P. 570 Dunlop, M.E. 499 Abraham, R.R. 889 Bischof, F. 1087 Chédin,P . 792 Durand,A . 570 Abumrad, N.N. 357 Bjaaland,T. 1020 Cherian, P.V. 602 Dyerberg,J. 447 Adamson,U . 287 Bjork,E . 490 Chikuba,N . 748 Agius,L . $34 Black,I . $18 ChisholmD,.J . 835 Akanuma,Y . 261 Blackman, J.D. 681 Chiu, K.C. 632 E Akazawa,S. 748 Blohmé,G . 56 ChristensenN,.J . 99 Akerblom, H.K. 70 Blom, L. 528, 1068 ChristiansenJ.,S . 1074 Edelstein,D . 96 Akkan, A.G. 505 Blondel,H . 792 Christie, M.R. 380 Edmonds, M.E. 148 Alberetto,M. 294 Blundell,T . S69 ChristopherM.,J . 399 EdmundsonA.,W . 857 Alford, F.P. 399 Boehm, B.O. 550 Clark, P.M. 444, 469, 1170 Efendic,S. 367 Almdal, T. 331 Boitard,C. 792,924,951, 1101 Clark, P.M.S. 192 Eizirik,D.L. 924 Altahir,H. 645 Bolinder,J . 664, 1042, 1177 Claude,J.-R. 39 Ekl6f, A.-C. 414 Alvarsson, M. 367 Bone, A.J. 238 Colditz,G.A . 967 Ekstrand,A . 1140 Alvestrand,A . 1042 Bonifacio,E . 385 Cole, D.R. 231 Elamin,A . 645 Amiel,S . S60 Borg, L.A.H. 939 Colle,E. 1118 Elts,S.M. 818 Andersen, P. 447 BornfeldtK.,E . 104 Collins, V.R. 534 Engstrém,A . 26 Andersen, P.K. 178 Bosi,E . 385 Corell,A . 475 Epstein, P.N. S23 Andersson, A. 490 Bottazzo,G.F. 32,385 Corrall, R.J.M. 991 Eriksson,H . 766 Anderton,C.D. 868 Bouchard, C. 653 Corriveau,M. 1118 Eriksson,J . 143,802, 1060, 1140 Andreani,D. 1093 Boulton, A.J.M. 660, 1146 Cotter,M.A. 12,946, 1011,1113 Eriksson, J.W. 510 Andreassen, T.T. 19 Bourey, R. 143, 1125 Cottrell,D.A. 676 Eriksson, L.S. 664 Andrews, J.W. 771 Boyle, P.J. 372 Coulic, V. 505 Eriksson, U.J. 517 Aoki,Y . 913 Bradish,G. 884 Cox, B.D. 192 Erkelens,D.W. 202,813 Aperia, A. 414 Brant, A.M. 304 Cox, L. 469, 1170 Erkisson,J . 291 Arnaiz-Villena, A. 475 Braulke,T . 216 Crace,C.J. 939 Eschwége,E . 39, 464 Arner, P. 664.1177 Bravenboer,B . 690,813 Crepin,K . 243 Arngvist,H.J. 56, 104 Brennan,G.M. 771 Crosby, S.R. 868 Ashcroft, F.M. 619 Brenner, H.-H. 1028 Cryer, P.E. 372 F Ashcroft,S.J.H. 619 Bretzel,R.G. 550 Cusin,I . 310 Atkison,P . 884 Brichard,S.M. 522 Czernichow, P. 577 Fabiano de Bruno, L.E. 1159 Auinger,M. 425 Brinchmann-Hansen,O. 1049 Fagius,J . 873 Avogaro, A. 129,372 Brown, M.B. 560 Fainboim,L. 1159 Awata.T. 419 Brown, T.J. 380 D Fajardy,I . 577 Brownlee,M. 96 Federlin,K . 550 Bruce,D.G. 835 Dahl-Jgrgensen, K. 1165 Ferguson,R.M. 676 B Brudzynski,K . 316 Dahlquist,G . 528,671, 980, Ferrannini,E . 697 Bruining,G.J. 139,436 1068 Ferraro, R.T. 753 Baarsma,G.S. 555 Bruno,G. 851 Damsbo, P. 80 Ferrie, J.E. 785 Bach, J.F. 792 Buren, T.van 813 Danielsen,R . 880 FitzgeraldA,.P . 192 Bader, S. 712 Burkart,V . 1028 Davies, J.A. 863 FlakollP,. J. 357 Baird,J.D. 231 Burnett,M. 469 Day, N.E. 192 Flier, J.S. 486 Bak, J.F. 777 Busson,M. 951 De Hertogh,R. 406 Flynn,M.D. 991 Balkau, B. 39 Byrne,C.D. 192 Dean,B.M. 385 Flyvbjerg,A . 589 Banga,J.D. 690 DeFronzo,R.A. 389 Fohlman,J . 249 Bangstad, H.-J. 1165 Deijnen,J.H.M.van 735 Fontbonne,A . 39,464 Bargero,G. 851 Del Maschio,A . 1002 FontvieillAe.,M . 753 Barker,D.J.P. 444,595 Del Prato, S. 310 Foriers,A . 1080 Barrett-Connor,E . 173 an)‘ ahane,M. 398 Delcourt, J. 406 Formanek,D . 425 Bartrons,R. 243 ‘aillat-Zucman,S . 792 Deschamps,I . 951 Foster, A.V.M. 148 Basabe, J.C. 1159 va‘natm eron,N.E. 12,946, 1011, Desoye,G. 45 Francis, P.J. 238 Bauer,I . 77 1113 Després, J.-P. 653 Franssila-Kallunki, A. 962, 1140 Beck-Nielsen,H. 80 “anela,J . 267 Diderholm,H. 249 Freund, P. 712 Beer, S.F. 277 ‘apron,F . 224 Dines,K . 946 Friman,G. 249 Bell. G.I. 743 ‘apron,L . 104 Dollinger,M. 1133 Frisk,G. 249 Bendtsen, T.F. 844 ‘apucchio,M . 1159 Donker, A.J.M. 555 Funk, B. 589 Bendtson, 1. 898 ‘arballo,E . 243 Doormaal van, J.J. 165 Fiirnsinn,C. 116 Benschop.C. 202 ardoso, A.I. 1159 Dorka,B . 589 Furuta,S. 913 Berger,M. 429,649, 1187 “arrascosa,J . 456 Dorman, J.S. 583 Berne,C . 873 ‘arson,D.J. 452 Dosch, H.-M. 985 Bertera,S. 583 RA‘RAa AssAiRdyA,DA .R A38D0 Dowse,G.K. 534,632 G Besch, W. 608 lan“ astell,C. 267 Drykoningen,C.E.M. 139 Best.J.D. 399.1055 Catterall,W . S23 Dubois, F. 577 Gade,J . 898 Betsholtz,C. 26,297 Ceisi,G. 414 Ducimetiére, P. 464 Gale, E.A.M. 32,385 Beusekamp, B.J. 165 Chakrabarti,S. 325,560,602 Dullaart,R.P.F. 165 Gall,M.-A. 447 Author index A Binder,C . 898 Chantelau,E. 191 Duner,E . 129 Bindra,D.S. 224 Chantres, M.T. 583 Dunger, D.B. 542 Aanstoot, H.J. 436 Bingley, P.J. 32 Chatelain, P. 570 Dunlop, M.E. 499 Abraham, R.R. 889 Bischof, F. 1087 Chédin,P . 792 Durand,A . 570 Abumrad, N.N. 357 Bjaaland,T. 1020 Cherian, P.V. 602 Dyerberg,J. 447 Adamson,U . 287 Bjork,E . 490 Chikuba,N . 748 Agius,L . $34 Black,I . $18 ChisholmD,.J . 835 Akanuma,Y . 261 Blackman, J.D. 681 Chiu, K.C. 632 E Akazawa,S. 748 Blohmé,G . 56 ChristensenN,.J . 99 Akerblom, H.K. 70 Blom, L. 528, 1068 ChristiansenJ.,S . 1074 Edelstein,D . 96 Akkan, A.G. 505 Blondel,H . 792 Christie, M.R. 380 Edmonds, M.E. 148 Alberetto,M. 294 Blundell,T . S69 ChristopherM.,J . 399 EdmundsonA.,W . 857 Alford, F.P. 399 Boehm, B.O. 550 Clark, P.M. 444, 469, 1170 Efendic,S. 367 Almdal, T. 331 Boitard,C. 792,924,951, 1101 Clark, P.M.S. 192 Eizirik,D.L. 924 Altahir,H. 645 Bolinder,J . 664, 1042, 1177 Claude,J.-R. 39 Ekl6f, A.-C. 414 Alvarsson, M. 367 Bone, A.J. 238 Colditz,G.A . 967 Ekstrand,A . 1140 Alvestrand,A . 1042 Bonifacio,E . 385 Cole, D.R. 231 Elamin,A . 645 Amiel,S . S60 Borg, L.A.H. 939 Colle,E. 1118 Elts,S.M. 818 Andersen, P. 447 BornfeldtK.,E . 104 Collins, V.R. 534 Engstrém,A . 26 Andersen, P.K. 178 Bosi,E . 385 Corell,A . 475 Epstein, P.N. S23 Andersson, A. 490 Bottazzo,G.F. 32,385 Corrall, R.J.M. 991 Eriksson,H . 766 Anderton,C.D. 868 Bouchard, C. 653 Corriveau,M. 1118 Eriksson,J . 143,802, 1060, 1140 Andreani,D. 1093 Boulton, A.J.M. 660, 1146 Cotter,M.A. 12,946, 1011,1113 Eriksson, J.W. 510 Andreassen, T.T. 19 Bourey, R. 143, 1125 Cottrell,D.A. 676 Eriksson, L.S. 664 Andrews, J.W. 771 Boyle, P.J. 372 Coulic, V. 505 Eriksson, U.J. 517 Aoki,Y . 913 Bradish,G. 884 Cox, B.D. 192 Erkelens,D.W. 202,813 Aperia, A. 414 Brant, A.M. 304 Cox, L. 469, 1170 Erkisson,J . 291 Arnaiz-Villena, A. 475 Braulke,T . 216 Crace,C.J. 939 Eschwége,E . 39, 464 Arner, P. 664.1177 Bravenboer,B . 690,813 Crepin,K . 243 Arngvist,H.J. 56, 104 Brennan,G.M. 771 Crosby, S.R. 868 Ashcroft, F.M. 619 Brenner, H.-H. 1028 Cryer, P.E. 372 F Ashcroft,S.J.H. 619 Bretzel,R.G. 550 Cusin,I . 310 Atkison,P . 884 Brichard,S.M. 522 Czernichow, P. 577 Fabiano de Bruno, L.E. 1159 Auinger,M. 425 Brinchmann-Hansen,O. 1049 Fagius,J . 873 Avogaro, A. 129,372 Brown, M.B. 560 Fainboim,L. 1159 Awata.T. 419 Brown, T.J. 380 D Fajardy,I . 577 Brownlee,M. 96 Federlin,K . 550 Bruce,D.G. 835 Dahl-Jgrgensen, K. 1165 Ferguson,R.M. 676 B Brudzynski,K . 316 Dahlquist,G . 528,671, 980, Ferrannini,E . 697 Bruining,G.J. 139,436 1068 Ferraro, R.T. 753 Baarsma,G.S. 555 Bruno,G. 851 Damsbo, P. 80 Ferrie, J.E. 785 Bach, J.F. 792 Buren, T.van 813 Danielsen,R . 880 FitzgeraldA,.P . 192 Bader, S. 712 Burkart,V . 1028 Davies, J.A. 863 FlakollP,. J. 357 Baird,J.D. 231 Burnett,M. 469 Day, N.E. 192 Flier, J.S. 486 Bak, J.F. 777 Busson,M. 951 De Hertogh,R. 406 Flynn,M.D. 991 Balkau, B. 39 Byrne,C.D. 192 Dean,B.M. 385 Flyvbjerg,A . 589 Banga,J.D. 690 DeFronzo,R.A. 389 Fohlman,J . 249 Bangstad, H.-J. 1165 Deijnen,J.H.M.van 735 Fontbonne,A . 39,464 Bargero,G. 851 Del Maschio,A . 1002 FontvieillAe.,M . 753 Barker,D.J.P. 444,595 Del Prato, S. 310 Foriers,A . 1080 Barrett-Connor,E . 173 an)‘ ahane,M. 398 Delcourt, J. 406 Formanek,D . 425 Bartrons,R. 243 ‘aillat-Zucman,S . 792 Deschamps,I . 951 Foster, A.V.M. 148 Basabe, J.C. 1159 va‘natm eron,N.E. 12,946, 1011, Desoye,G. 45 Francis, P.J. 238 Bauer,I . 77 1113 Després, J.-P. 653 Franssila-Kallunki, A. 962, 1140 Beck-Nielsen,H. 80 “anela,J . 267 Diderholm,H. 249 Freund, P. 712 Beer, S.F. 277 ‘apron,F . 224 Dines,K . 946 Friman,G. 249 Bell. G.I. 743 ‘apron,L . 104 Dollinger,M. 1133 Frisk,G. 249 Bendtsen, T.F. 844 ‘apucchio,M . 1159 Donker, A.J.M. 555 Funk, B. 589 Bendtson, 1. 898 ‘arballo,E . 243 Doormaal van, J.J. 165 Fiirnsinn,C. 116 Benschop.C. 202 ardoso, A.I. 1159 Dorka,B . 589 Furuta,S. 913 Berger,M. 429,649, 1187 “arrascosa,J . 456 Dorman, J.S. 583 Berne,C . 873 ‘arson,D.J. 452 Dosch, H.-M. 985 Bertera,S. 583 RA‘RAa AssAiRdyA,DA .R A38D0 Dowse,G.K. 534,632 G Besch, W. 608 lan“ astell,C. 267 Drykoningen,C.E.M. 139 Best.J.D. 399.1055 Catterall,W . S23 Dubois, F. 577 Gade,J . 898 Betsholtz,C. 26,297 Ceisi,G. 414 Ducimetiére, P. 464 Gale, E.A.M. 32,385 Beusekamp, B.J. 165 Chakrabarti,S. 325,560,602 Dullaart,R.P.F. 165 Gall,M.-A. 447 Galuska,D. 26 Hother-Nielsen,O. 80 Keymeulen, B. 719, 1080 Lledo,G . 475 Genovese,S . 385 Houwing,H. 917 Kiess, W. 589 Lloveras,G. 267 Gerbitz,K.D. 183 Howell, S.L. 1020 Kim, H. 261 ia;3:3:S: 277 Gerbitz, K.-D. 1181 Hubbard,R. S69 Kivinen, P. 760 Lénnroth,P. 510 Gibbs, E.M. 304 Hiibinger,A . 828 Kiyosawa,K. 913 Lounamaa, R. 70 Gilcrease,M.Z. 160 Hue,L. 243 Klein, D.J. S8 Love,A . 946 Gispen, W.H. 813 Hyoty, H. 63 Kléppel,G. 272 Lucke,S. 608 Giugliano,D. 698 Kneteman, N.M. 89 Gliick,M. 550 Knight,L.T. 534 Gnudi,L. 129 Knowles,W . 996 M Goday,A . 267 Kofoed-Enevoldsen, A. 1165 Goodnow,C.C. S49 Ibbotson,S.H. 863 Kohler, E. 608 Macdonald, I.A. 287 Gordon,C . 868 Imam,S.Z. 452 Kohner, E.M. 190 Mackay, I.R. 996 Gorus,F. 719 Imura,H. 1035 Kohonen-CorisM.hR.,J . 996 Madsen,O.D. 272 Gorus, F.K. 1080 Int Veld,P.A. 272 Koike,T . 1028 Maeda,Y . 748 Gould, G.W. 304 In't Veld, P. 719 Koivisto, V. 347 Makarovic,M . 1002 Grabensee,B . 1187 lori,E . 129 Kolb-Bachofen, V. 331,796 Makino,H . 639 Grant,P.J. 863 Irsigler, K. 425 Kolb,H . 796, 1028 Malaisse-Lagae, F. 505 Green,A . 178 Ishida,H. 1035 Kollind, M. 287 MalaisseW,.J . 505 GreenbaumC,.J . 798 Ismail,B . 645 Kono,N . 614 Mandrup-Poulsen, T. 331 Greene,D.A. 560 Iwamoto, Y. 419 Koranyi,L. 143, 1125 Mangili,R. 1002 Gries,F.A . 828, 1099 KG6rner, A. 414 Manson, J.E. 967 Grill,V . 367 Kortlandt,W . 202 Maran,A . 129 Groop, L. 291, 802,962, 1140 J Koskenvuo, M. 1060 Marcelli-Barge,A . 951 Groop,L.C. 143 Koskinen,L . 63 Marchand,J . 505 Gu, X.F. 577 Jaffa, A.A. 857 Kowluru, A. 624 Marescotti,C. 129 Gu, X.-H. 889 James,D.E. S41 Kowluru, R.A. 624 Marmot,M.G. 785 Gupta, R.S. 316 Janjic,D. 482 Kraegen, E.W. 835 Marshall,S.M. 1074 Gutierrez-Lopez,M.D. 583 Janus,E.D. 1055 Kranenburg,G. 436 Martin, L.L. 857 Jarrett,R.J. 192 Krentz, A.J. 1170 Martin-Villa,J.M. 475 Jeanrenaud, B. 310 Krijger, R.R.de 436 Martinez-Laso, J. 475 H Jenkins, A.B. 208 Kréncke, K.-D. 331 Martinez, V. 316 Jenkins, A.J. 1055 Krook,A . 486 Mathaei,S. 712 Haffner,S.M. 697 Jenkins, J.G. 452 Kurose,T. 1035 Matsuda, A. 419 Hagstrém-Toft,E . 664 Jenner,M. 884 Kusunoki,M. 208 Matsukura,S. 291 Hakura, A. 614 Jensen, B. 447 Kuzuya,T. 419 Matthews, D.R. 32,542,696 Hales,C.N. 192, 444, 469,595 Johansson, B.-L. 121, 1151 Mau Pedersen, M. 1074 Hamers, F.P.T. 813 Johansson,U . 664 Mayfield, R.K. 857 Hanafusa,T . 614 Johnson, K.H. 26,297 McClure, B.G. 452 Hansen, K.W. 1074 Johnston,G.D. 771 McCoid, S.C. 304 Hanssen, K.F. 1049, 1165 Joner,G. 1049 Lafferty, K.J. 436 McDermottB,.J . 771 Haring,H.U. 456,712 Jones,P.M. 1020 Lahrmann,H . 425 McGrathL,.T . 771 Harris, N.D. 155 JongkindJ,.F . 436 Laitinen,J . 340 Mcintyre,M. 231 Hartmann, H. 216,932 Jorde,R. 958 Landin-Olsson, M. 980, 1068 McKeigueP,.M . 785 Harvey,J.N. 857 Juan,D.de 475 Lansimies, E. 340 McNally, J.M. 385 Hashimoto,N . 639 Lantos,J . S60 McVeigh, G.E. 771 Hawa,M. 277 LaPorte,R.E. 139 Meijer,S . 165 Hayes, J.R. 771 K Larkins, R.G. 499 Merkle,M. 425 Hehmke,B. 608 Larsson,B . 766 Meyer-Alber, A. 216 Heinemann, L. 649 Kaarsalo,E. 760 Laudadio,C. 560 Meyerhoff,C. 1087 Helgason,T . 880 Kadowaki,H . 261 Leclercq-Meyer, V. 505 Minei,A . 698 Hellerstr6m,C. 1 Kadowaki,T . 261 Lee, W.C. 973 Miola,M. 129 HendriksenP,.H . 690 Kahn, B.B. 304 Lefébvre, P.J. 494,1188 Miralpeix,M. 243 Hennekens, C.H. 967 Kahn,C.R. 109 Leighton,B . 801 Mitchell, B.D. 697 Henquin, J.C. 522 Kahri,J . 347 Leinikki, P. 63 Mitchell, R.H. 452 Henquin, J.-C. Kallén,B . 671 Lemieux,S . 653 Miyagawa,J . 614 Henry, M.L. 676 Kampe,O. 490 Lernmark,A . 1068, 1096 Miyamoto,T . 748 Henry, W.R. 771 Kanazawa,Y . 419 Leslie, R.D.G. 277 Miyazaki,Y . 261 Hering,B . 550 Kappelle, A.C. 813 Levy, D.M. 889 Miyazato,M. 291 Herold, K.C. S49 Kaprio, E.A. 70 Levy, J.C. 469 Mizisin,A . S18 Hill, J.O. 357 Kaprio,J . 1060 Lévy-Marchal,C. 577 Moller,N . 777 Hilsted,J. 99 Karjalainen,J . 985 Liener,K . 116 Moatti-Sirat,D. 224 Hjemdahl,P . 873 KarlssonF.,A . 490 Lillioja,S. 753 Moberg, E. 287 Hofmann, H.H. 45 KarvonenM,.J . 760 Lin, R.S. 973 Mogenet,A . 951 Hollenstein,U . 116 Kasuga, M. 261 Linde,B . 1151 Mogensen,C.E. 1074 Hommel, E. 447 Kato,S . 1035 Linné,T. 414 Moller, D.E. 486 Hoogenberg, K. 165 Kawasaki,E . 748 Lins, P.-E. 287 Moller, E. 283 Hoover, R.L. 160 Kellerer,M. 712 Lisato,G. 310 Momomura,K . 261 Hopmeier,P . 77 Kemmer, F.W. 1187 Lithner,F. 56 Morales, P. 475 Hors,J . 951 Kesaniemi, Y.A. 1060 Littorin,B . 56 Morgan,R . 486 Hosaka, Y. 730 Kessler,U . 589 Liu,D . 287 Moriuchi, R. 748 Mortensen Mortensen, K. 178 Pal, B.R. 542 Rollins, M.D. 452 Sleeman,M.W. 399 Mota, A.H. 1159 Palmer, J.P. 798, 1068 Romanov, K. 1060 Sluiter, W.J. 165 Mueckler, M. 143, 1125 Pampfer,S. 406 Rosa,N.De 698 Smith, L. 372 Miihlbacher,C . 456 Papoz,L. 173 Rosner,B . 967 Smith, U. 510 Miihlen,H. 828, 1099 Parkkonen,P. 63 Ross, R. $34 Smythe,G.A. 835 Miihlhauser, 1. 429 Parving, H.-H. 447 Rossing,P . 447 Sodoyez, J.-C. 1080 Mulder, A.L.M. 139 Pascoe, W.S. 208 Rousseau, G.G. 243 SouthgateJ.,L . 238 Murray, H.J. 660 Pearson, J.D. 1020 Rowley, M.J. 996 Speizer, F.E. 967 Mushack, J. 456 Pedersen,O. 777 Ryan, E.A. 89 Springall,D.R. 889 Pekkanen,J . 760 SroczynskiJ.,W . 1173 Peltonen,L . 254 Stampfer, M.J. 967 N Pennock,C.A. 991 S Starke,A . 649 Permutt, A.M. 143 Steele, J.S. 1055 Nadeau,A . 653 Permutt,M.A. 632 Saaek, A. 777 Stefanutti,A . 570 Nagataki,S. 748 Persaud, S.J. 1020 Sager,G. 958 Stehouwer,C.D.A. 555 Nahoul,K . 173 Persson,B . 414 Saint-Paul,M. 173 Steiner,D.F. S41 Nakagawa,C. 614 Persson, L.A. 528 Sakura,H. 261 Stengard,J. 1060 Nakajima,H . 614 Petersen,J . 570 Saloranta,C. 1140 Stengard,J.H. 760 Nakazato,M . 291,802 Pfeiffer,E.F. 1087 Sandler,S . 924 Stenvinkel, P. 1042 Nattrass,M. 1170 Phillips, J.W. 818 Sanjeevi,C.B. 283 Stern, M.P. 697 Nauta, J.J.P. 555 Phillips, P.-E. 542 SantamariaJ.,D . 1055 Sternberg,F . 1087 Nerup,J . 331 Pierpoint,T. 785 Santiago, J.V. 372 Stevens,M.J. 148 Nielsen, F. 447 Pipeleers,D.G. 719, 1080 Sarvetnick,N. $1 Stiller,C. 884 Nishi,S . 743 Pisu,E. 851 Saukkonen,T . 985 Stoffel,M. 743 Nissinen,A . 760 Poitout,V . 224 Savilahti, E. 980,985 Storlien, L.H. 208,835 Nosadini,R. 129 Polak, B.C.P. 555 Sawicki, P.T. 649 Strandell,E. 924 Nossal, G.J.V. $49 Polak, J.M. 889 Schalin-Jantti,C. 143, 1140 Stratton, I.M. 696 Nowotny, P. 116 Pollare,T. 873 Scherbaum,W . 570 Strik,R.van 436 Nozaki,O . 639 Polonsky, K.S. 681 ScherbauWm., A . 550 Strojek, K. 1173 Nyengaard,J.R. 844 Pongratz,D. 456 Schernthaner, G. 77,904 Strubbe, J.H. 917 Nystrém,L . 56, 1068 Pontiroli, A.E. 294 Scherstén,B . 56 Strynadka, K. 409 Poskus,E. 1159 Schilfgaarde,R.van 735,917 Stiimpel,F . 932 Pozza,G. 294, 1002 Schleicher, E.D. 183 Sturis,J . 681 O Pozzilli, P. 1093 Schlosser,M. 608 Suarez, W.L. 409 Prashar, A. 560 Schmid, R. 1133 Sulzer,M. 429 @Mrskov.C. 701 Pregant,P . 77 Schmitz,O. 777 Sundkvist,G. 1068 @rskov,H . 589 Preziosi,P . 173 Schnack,Ch . 77 Sundsfjord,J . 958 @Msterby,R. 803 Province,M.A. 6: SchnackC,H . 904 Suylichem, P.T.R.van 917 Obermaier-Kusser, B. Prudhomme, D. Schnell Landstr6ém, A. 939 Suzuki, Y. 639 O’Brien, T.D. 297 Pyke, D.A. 277 Scholz, R. 712 Svardsudd, K. 766 Odawara,M . 261 Schravendijk,C.F.H.Van 1080 SvendsenA,.J . 178 O’Dorisio. T.M. 676 Schulz, L.O. 753 Swenne,I. 193,939 Oey, P.L. 690 Q Schusdziarra, V. 1133 Oguchi,H. 913 Schwaabe,S. 183 Ohlson, L.-O. 766 Quatraro, A. 698 Seemayer, T.A. 1118 T Ohtaka,M . 730 Quetin,C. 398 Seffer,E. 456 Ohtani,T . 261 Segurado,O.G. 475 TabernerJ,.L . 267 Okamoto,Y . 1035 Seino, Y. 1035 Taira,M. 639 Oklek.K . 1173 R SeiBler,J . 550 Takahashi,Y . 261 Okuno,S. 748 Serjeantson,S . 632 Takao, Y. 748 Olerup,O. 283 Rabinovitch, A. 89, 409 SerjeantsoSn.,W . 996 Takeda,J . 743 Olgemiller, B. 183 Rajotte,R.V. 89 Serrano-Rios, M. 583 Takino,H . 748 Olsson, P.O. 56 Rankel,G. 1002 Seshiah,V . 283 Tannous, W.N. 1118 O'Meara, N.M. 681 Ravussin,E . 753 Shah,S.D. 372 Tappaz,M. 570 Onaya, T. 730 Reach,G. 224,398 Shapiro, E.T. 681 Tarui,S. 614 Ongemba,L.N. 522 Rees, A. 486 Shepherd,J . 347 Taskinen, M.-R. 347 Oosawa,Y . 619 Reimers,J . 331 ShepherdP,.R . 304 Tawata, M. 730 O’Rahilly,S. 486 Rett,K. 712 Shimada, F. 639 Taylor,S.1. 261 Orgiazzi,J. 570 Reunanen,A . 70,1060 Shiemi,K . 291 Teng,H. 719 Osei,K . 676 Rice, D.E. 357 Shizuru,J.A. $1 Terenghi,G. 889 Osmond, C. 4 Richter, W. 550 Shows, T.B. 743 Tesfaye,S. 155 Ostman,J . 56 Rijn van, H.J.M. 202 Siegler,M. S60 Tesi, R.J. 676 Ottolander,G.J.H.den 55: Rimm, E.B. 967 Signore,A . 1093 Theilgaard,A . 898 Oxlund,H. 19 Rising, R. 753 Siitonen,O. 340 Thévenot,D.R. 224 Robert, J.-J. 951 Sima, A.A.F. 325,560, 602 Thibult,N . 464 RobertsonR,.P . S8& Simmons,D.A. 725 Thivolet,CH. 570 P Robertson,S . 12,1113 Simon,D . 173 Thomas, P.D. 409 Robin,D . 406 Simpson,I . 409 ThorssonA,.V . 880 Packard, C.J. 347 Robinson,S. 444 Sironi,S. 1002 Tibblin,G . 766 Paepe De,M.E. 1118 Roden,M. 116 SjOberg,S. 121 Tichet,J . 577 Pagano,G. 851 Roger, M. 173 Slama,G. 398 TienariP,. J. 254 1194 Zwick Tiengo,A . 129,310 Valk,H.W.de 904 Warnock, G.L. 89 - Timsit,J . 792 Van Cauter, E. 681 Waterfall,M . 231 Tippmer,S . 712 Vanderheyden,I . 406 WatersP,. J. 991 Yamamoto,H . 748 Tomita,K . 614 Vanninen,E. 340 WatkinsP,. J. 2,148 Yamamoto,K . 614 Torres,C.G. 1049 Vavassori,C. 583 Weatherall,D. $1 Yamazaki, A. 624 Tremblay, A. 653 Vea,H. 958 Weigert,N. 1133 Yanagisawa,Y . 913 Tresserras,R. 267 Verkerk, A. 436 Weiss,M.A. S69 Yassin,N . 550 Trucco,M. 583 Vetri,M. 719 Weiss, P.A.M. 45 Yazaki,K . 913 Tsigos,C. 868 Veves, A. 660, 1146 Welin,L . 766 Yazaki,Y . 261 Tsuda,K . 1035 Vialettes,B. 570 Wentzel, L.S. 357 Yokota, A. 748 Tsuji,K . 1035 Vicario, J.L. 475 Westermark, P. 26,297 Yoshida, S$. 639 Tsuura, Y. Vierhapper,H . 116 White,A . 868 Young, M.J. 660, 1146 Tuomilehto, J. 70,254,760, Villanove-Robin, F. 398 Wibell,L . 56 Young, R.J. 868 1060 Virtala,E . 70 Widén,E . 143, 1140 Yutsudo, M. 614 Tuomilehto-Wolf, E. 70,254 Vogt,B. 456 Wieneke,G.H. 690 Turk,J. 1125 forberg, E. 699 Wilkin, T.J. 187,238,798 Turner, R.C. 469 Vos-Scheperkeuter, G. H. Willett, W.C. 967 Z Turner, R.L. 696 35 Williams, A.C. 1170 Tuvemo, T. 249,645 Vuolo, A. 851 Williams, A.Jj.K. 32 Zavala,A.V. 1159 Williams,D.R.R. 192 Zellenrath, P. 555 Williams, K.A. 818 Zerbini,G. 1002 U Ww Wilson, G.S. 224 Zhang, F. 272 Wilson, R.M. 155 Zhang, W.-X. Unger, E. 517 Wagner, G. 632 Winegrad, A.I. 725 Zhang, Y. Ungerstedt, U. 664, 1177 Wagner, R. 385 Witt,S . 608 Ziegler, B. Usami,M. 1035 Wahren,J . 121,1151 Wogensen,L.D. 331 Ziegler, D. 828, 1099 Uusitupa, M. 340 Waldhausl,W . 116 Wollheim, C.B. 482 Ziegler,M. 608 Walker,M.G. 1146 Wolters, G.H.J. 735,917 Zier, H. 1087 Wallberg-Henriksson, H. Wong, H.C. 818 Zierath,J.R. 26 Vv Walmsley,D. 863 Wong, J.S.K. 190 Zimmet, P. 996 Walton, R.J. 444 Zimmet, PZ. 534,632 Vaag, A. 80 Wang, T.W.N. 192 Ziora,D 1173 Vaaler,S. 958 Wanke,T. 425 X Zoppini,G. 109 Vaandrager,G.J. 139 Ward, J.D. 155 Zwick,H . 425 Valerio, A. 129 Warnet,J.-M. 39 Xiang, K Subject Index KEY:A = Abstractin Supplement 1;b = Book review;c = Correspondence;r = Review or Debate;S = Supplement 2;w = Workshop report A — — vasomotor deficiency in diabetic rat, — HLA 996, A 50 effecton 1011 — monoclonal A 51 Acarbose /see a-glucosidase inhibitor/ — — WAY-121,509 A 49 — pancreatic histology A 41 Adenosine — vasodilator effect — glucose — — zopolrestat— renal hyperfiltration — — persistence—Type 1DM A 209 concentration and 725 diabetesrat A 148 — prediction of diabetes Type 1 570 Adhesion — /see also Monocyte/ Alloxan — diabetes — protection — glutathio- insulin auto — assay —standardisation — molecule — circulating — diabetes — Ty- ne isopropylester A 201 798w pel A33 a-glucosidase inhibitor — acarbose — BB rat — diabetes — secondary failure of tablet Adipocyte — membrane — glucagon & GLP- —neuropathy 325 treatment 1159 1(7-36) amide receptors A 76 — — multicentre trial A 15 — insulin bindingi n vivo, effecton A 81 — metabolism — glucose feeding, effect of — miglitol A 15 — prediction of diabetes Type 1 1068 A 102 Aminoguanidine —albuminuria, effect on — prevalence 570 Adipose tissue /see also Fat/ 96 — relatives of Type 2diabetics A 208 insulin, effect of —catecholamine interac- collagen glycation, effect on 19 islet-cell— antigen A 208 tion 664 diabetic neuropathy, effect on — strepto- — — ganglioside GM2-1 A 42, 380, 385, lipogenic enzyme expression — glucose, zotocin-diabetic rat 946 490 effect of A 17 lipoperoxidation end-products, effect childhood —- Sardinia A 32 - metabolism 664 on A55 cytoplasmic — heterogeneity & selec- — — sympathetic nervous system, effect of Amylin 297r tivity 385 A 101 antibodies—spontaneous 1080 diabetes — gestational A 211 — microdialysis 664 expression, islet A 57 — Type 1-HLA-DQ A50 Adolescence — diabetes — Type 1 — retino- — GLUT-2expression and 1125 - Type2 A210 pathy 1049 gene —regulation A 85 endocrine cells — diabetes — Type 1 Adrenaline — capillary permeability, effect glucose transport, effect on — skeletal A 209 on 99r muscle 26 gestational diabetes — subsequent glycogen metabolism, effect on — skeletal human - transgenic mouse, in — localisa- IVGTT A27 muscle 399 tion in pancreas A 81 glutamic acid decarboxylase /see Anti- ketogenic effect—insulinand 129 infusion — intraportal — insulin resistance body — glutamic/ vasoconstrictor effect — glucose concen- in A89 heterogeneity — diabetes— Type 1 792 tration and 725 insulin secretion, effecton A 115 insulinoma cell reactivity A 207 Adrenoceptor — @ — blocking agent — insulinoma,in A 118,A 119 monoclonal—human A 42 SL 84.0414 — metabolic effects liver, effecton 116 — lack of betacytotoxicity in vivo 608 A 104 pancreas — human fetal 272 - M, 64, 000 — prediction of Type 1 diabe- Aetiologic fraction 475 plasma - relatives of Type 2 diabetics tes 550 AIDSPIT (Artificial Insulin Delivery Sy- 291,801 — Type Idiabetes A 209 stems Pancreas & Islet Transpltn Study — secretion— obesity A115 — — longstanding 748 Group) Anaerobic threshold — exercise & diet, ef- oscillatory insulin secretion 32 EASD News Section 25 Following page fect of -Type 2diabetes 340 — prediction of Type I diabetes 955, 1068 594 w Angiotensin — II — vasoconstrictor effect — — prevalence —childhood—France 570 Albert Renold Fellowship 1992 Following glucose concentration and 725 monoclonal — endocrine pancreas 436 page 1010 converting enzyme inhibitor — diabetes Antidiabetic drug /see Hypoglycaemic Albumin — excretion rate /see also Micro- A 93 agent/ albuminuria/ — — lisinopril 12 Aorta—Na*/K* ATPase - glucose concen- insulin, effect of 99r — —-— microalbuminuria A 148 tration, effect of 725 Albuminuria — diabetes aminoguanidine, — — muscle, effect on—diabetic rat 12 rabbit intima-media preparation 725 effect of—rat 96 — — nerve, effect on-diabeticrat 12 rat—streptozotocin-diabetic 1011 sorbinil, effect of streptozotocin-dia- Antiandrogen — flumetanide — insulin resis- Apolipoprotein — A — plasma — microalbu- beticrat 414 tance, effecton A 86 minuria—Type 2diabetes 1055 Alcohol - mortality—diabetes 39 Antibody — advanced glycation endproduct A-I- metabolism — Type | diabetes 347 Aldose reductase — aorta streptozotocin- -HLA A 208 A-II- metabolism —Type | diabetes 347 diabetic rat 1011 amylin auto- 1080, A 209 A-IV—Type 2diabetes A 168 expression — calf pulmonary artery endo- autonomic nervous tissue — diabetic neu- B - lipoprotein synthesis regulation, role thelial cell 730 ropathy A 156 in Al7 retinal epitheliacle ll A 139 B-lactoglobulin — diabetes — Type 1 B — metabolism — glycation, effect of 202 inhibitor (4-amino-2-6-dimethylphenyl- A 208 E — polymorphism — Type 2 diabetes & sulphonyl)nitromethane A 203 ~ risk of diabetes— Type 1 980, A 24 gender A 63 lens epithelial cell myo-inositol, effect bovine serum albumin —assay 985 polymorphism — coronary heart disease — on A 104 — diabetes—Type 1 985 diabetes A 64 ponalrestat A 203 ganglioside — diabetes— Type 1 A 209 Artery — carotid — atherosclerosis — diabe- retina, effect on galactose-fed dog glutamic acid decarboxylase — 64 & 67 tes A 96,A 95 A 143 A 50 Ascorbic acid — metabolism — renal and neu- sorbinil 414 —- assay A 50 ral-BBrat All TAT - diabetic neuropathy, effect on - — — brainextract A 206 Assay —immunoradiometric — proinsulin A 151 — — diabetes—Type 1 996 and products 469 Cystic fibrosis Astrocyte — insulin effects — signal transduc- Na’ channel - insulin secretion, inhibi- Cardiovascular — risk factor — Paris prospec- tion—-IGF comparison A 99 tionof A 120 tive study 464 Atherogenesis S 34w platinum toxicity A 49 Care of diabetes /see Diabetes — care/ Atrial natriuretic factor — plasma — hyperin- protection /see Alloxan; Immunothera- Catalonia —diabetes—Type 1 267 sulinaemia, in 1042 py; Nicotinamide/ Cataract — diabetes — lipid peroxidation in Autocorrelation 32 regeneration — promoter — nicotinamide A 46 Autoimmunity — anti-islet 1101r A 115 Catecholamine — diabetes Type 2, effects cell-mediated — diabetes Type 1 A 213, replication—diabetes 193r in 835 A 215 residual — identification by in-situ hypri- CGRP (Calcitonin gene related peptide) diabetes Type 1 187 disation A 80 297r — follow-upstudy A 214 selective destruction in vivo — streptozo- — degradation -skeletal muscle A 18 function 187 tocin, mesenteric A 79 Charcot arthropathy — selective neuro- - insulinoma-cell — passive transfer - NOD Basal metabolicrate—diabetes—Type 2 962 pathy 148 mouse A 23 Bergman minimal model method 676 Cheiroarthropathy — diabetic — microangio- islet — diabetes — secondary failure of ta- B-cell [see B-cell, islet] pathy, association with? A 191 blet treatment 1159 B-hydroxybutyrate /see Ketones/ Cholecystokinin — receptor — subtypes — is- tolerance diabetes — Type 1 S 49w Bladder function — diabetes — ganglioside let A85 derivatives, effect of A 151 Cholesterol — synthesis — hyperinsulinae- Blood — arterialised venous — glucose sam- mia, effectof A 63 pling 287 — transport-— reverse — Type | diabetes coagulation /see Haemostasis/ A 64 B-cell, islet /see also Insulin — secretion; — flow-cerebral—diabetes A 173 Chromogranin A — converting enzyme Islet/ - — Charcot foot 148 endopeptidase A 107 acetylcholine, effects of -Na* and — — diabetic foot — laser doppler study Cirrhosis — fructose as carbohydrate sour- Ca’* A 100 A 159 ce A107 autoimmunity 1101r diabetic neuropathy 2r Clamp-—euglycaemic A 28 or —channel-—types A 121 nerve 1113 — — hyperinsulinaemic 777 — culture duration, effect of A 99 — diabetic neuropathy, role in 1146, — — — fa/farat—vanadate 522 oscillation A 13 155 — human 357 — cAMPsynchronisation A 58 group — maternal-child incompatibility — — persisting endogenous glucose — Na‘/K™ pump inhibition, effects diabetes Type i risk factor 671 prodn A7 of A122 pressure — ambulatory monitoring 1074 — rat 310 protein kinase C, effect of A 100, — — ambulatory monitoring — microalbumi- — sympathetic nervous response 873 A 101 nuria—diabetes A 163 rat—IGF-Il effect 932 Type | diabetic serum, effect of circadian variation — diabetic nephro- — non-esterified fatty-acid 372 A 58 pathy 1074 Claude Bernard Lecturer 1992 —- Bennett, cell-mass — malnutrition in early life, ef- — — diurnal rhythm-—diabetes A 154 PH Following page 1010 fect of 939 — — von Willebrand factor and 555 Coeliac disease —-diabetes— Type 1 A 211 cellular & molecular biology S 41 w Body — composition —- Pima Indians 753 Cognitive function — hypoglycaemia — noc- cytokine toxicity — free radicals involved — fat distribution /see Fat — distribution/ turnal 898 409, 796 — weight — diabetes incidence and — Swe- — — previous glycaemia, effect of 828 function — assessment — assay of proinsu- den 56 — Reavenssyndrome A 97 linand products 469 Bone — mineral density /see also Osteoporo- Collagen — glycation — aminoguanidine, ef- - — diabetes Type 1 —at clinical onset sis] fectof 19 A 124 — — diabetes A 191, A 192 — rat tailtendon-—diabetes 913 — — before onset 277 — turnover-—diabetes A 192 — thermal stability — Vitamin E, effect of — — - Erratum 1100 Brain — glucose transporter 304 913 glucokinase — microsatellite DNA poly- — pericyte — growth — glucose, effect of 818 Collagenase — islet isolation, use in 735 morphism 743 Complement — C4B — prediction of Ty- — — Erratum 1100 pe I diabetes in siblings 955 glucose-unresponsive — leucine, stimula- € Complications of diabetes — lysosomal enzy- tionby A 111 mes, plasma 991 granule —electron density A 125 C-peptide — actions — muscle, exercising — pulmonary function abnormalities HLA expression — Class I—- mumps virus 1151 1173 63 actions — muscle, exercising A 65 — quality ofcare 429 HSP60 related protein - NOD mouse - glomerular function, effecton 121 — redox abnormalities, role of A 46 316 plasma — arginine, response to 367 Computer — simulation — blood glucose re- human -—cell separation 436, A 119 release — insulin release, relation to sponse to exercise & diet A 164 interleukin 1b, effect of 331 A 115 Congenital malformation /see Teratogene- K* channel —- ATP-dependent — rund- renal function, effecton A 146 sis/ own A 121 secretion — diabetes — Type 2— normogly- Contraception — oral — risk of diabetes — Ty- — ATP-dependent — trypsin, effect of caemia duration, effect of A 105 pe2 967 A 117 Cadherin — islet-cell— molecular cloning Cryopreservation —humanislet 89 * *a“ * -activated — assay — planar lipid bi- A 57 CSII /see Insulin — infusion —subcutaneous/ layer 619 Calcitonin — gene — related peptide /see Cycle — ergometer test 425 — low-conductance — oscillations A 58 CGRP/ Cyclosporin A —childhood diabetes 884 membrane potential — Ca” * fluxes, role Calorimetry -—indirect 753 — insulinresistance A 98 of A99 Capillary permeability 99r insulin secretion, effecton A 39 MHC expression — Class II — antigen pre- — islet—diabetic BBrat 1118 Cystic fibrosis—diabetes A 140 sentation? A 23 — protein A-gold immunocytochemistry — — insulin secretion, early imparimento f mitochondrial metabolism A 116 1118 A 110 Cytokine — glucose tolerance — prospective study insulin resistance, effect on - mouse — — diabetes 771 A 141 A 49 — function —von Willebrand factor 555 Cytokine — islet toxicity dorsal vs. ventral — rat 208 — permeab—i insulliin, tefyfe ct of A 18 islets A 128 monounsaturated A 31,A 40 Endothelin — plasma — diabetes Type 1 - muscle glucose update, effecton A 17 vasodilation A 19 §2; fatty acids /see Diet — fat — fish oil/ — — microalbuminuria A 170 D §2, polyunsaturated fatty acids — gluco- — secr—e exetrciiseo, enff ect of A 19 se tolerance, effecton A 40 — — insulin, effect of A 19 Dawn phenomenon A 195 fibre — glucose homeostasis, effect on Endotoxin — monocyte activation 160 growth hormone deficiency, absence in A 165 Energy — expenditure — diabetes — Type 2 - 372 fish — coronary heart disease mortality Pima Indians 753 Denmark — diabetes incidence 178 A 166 Epidemiology /see also Mortality/ Desferrioxamine — diabetes A 202 guidance by pocket computer system — age-period-cohort analysis — diabetes Dexamethasone — insulin response to argi- A 164 mortality 973 nine, effect on 367 haemodialysis— diabetes A 165 diabetes —childhood-—England A 130 Diabetes —care-—delivery A 174 maternal — diabetes Type 2 pathogenesis — Denmark 178 hospital admission—children A 176 595r — incidence — age 15-34 quality —assessment 429, A 52 meal frequency — diabetes — Type 2 — Italy A 133,851 improvement —Diabcare A 51 A 166 — Netherlands 139 Sudan 645 protein — restricted — renal function, ef- — Russia A 130 economics A 175 fecton-—diabetes A 148 study group /see EDESG/ malnutrition-related — genetic difference weight-reducing — glucose homeostasis Sweden 56,70 from Type ldiabetes 283 A 166 Taiwan 973 Textbook — Alberti, De Fronzo, Keen & DNA - damage —islet A 127 Type 1 56,70 Zimmet 1009b — mitochondrial — diabetes pathogenesis, — age-infectionand A 25 Pickup & Williams 1009b rolein? 1181r Bulgaria A 131 Type 1 /see also Islet; Mouse - NOD; Rat DPSG (Diabetic Pregnancy Study Group Catalonia 267 BB/ Following page 192w clustering A 24 autoimmunity /see Autoimmunity — - Europe A 24 diabetes/ Iceland 880 epidemiology /see Epidemiology/ E Ireland A 131 gen/esee talsio Gcenestic s/ maternal-child blood group incom- factors — environmental factors and EASD — General Assembly (Supp! 1) I patibility 671 70 — News Section Following pages 98, 192, - Netherlands A 130 prediction /see Prediabetes; Predic- 296, 398, 497, 594, 802, 906, 1010, 1100 Portugal A 130 tion] — Study Group — Metabolism & Insulin Ac- rising incidence 139,178 slowly-progressive A 210 tion Following p. 296 Sardinia A 25 treatment /see also Dawn phenome- EASDEC (European Assoc’n for Study of seasonality —g ender effect A 131 non; Insulin/ Diabetic Eye Complic’ns) 190w - Slovakia A 131 Type 2 /see also Insulin — resistance; Rea- EASDEC Following page 398 — Sudan 645 ven’s syndrome/ EDESG Following page 497 Type 2 56 obesity — treatment A 195 Editorial 1 — Finland-elderly A 132 pathogenesis 389r EDNSG (European Diabetic Nephropathy — Melanesia A 133 intrauterine and neonatal nutrition Study Group) Following page 398 - — oral contraceptive users 967 595r Education — diabetes — evaluation A 52 — — Papua New Guinea A 132 thrifty phenotype hypothesis 595r — insulin treatment /see Computer; Insulin — — South Africa A 133 rat model 208 —treatment/ hyperinsulinaemia — Chinese in UK treatment /see also Diet; Exercise; Hy- Elderly —diabetes in 98b A 134 poglycaemic agent/ — mortality— glucose tolerance and 760 - — Nau&r Tuuval u 534 exercise & diet 340 Electrocardiogram — diabetes — childhood - islet-cell antibody & Type 1 diabetes — Diabetologia —circulation policy 1 power spectral analysis 452 Estonia & Finland A 218 Diacylglycerol — diabetic nephropathy, role — neuroleptic therapy, effect of — diabetes Westernisation, effect of -M elanesia in 499r A 153 A 133 Diet — diabetes— European survey A 164 Electroencephalography — P300 potentials — Epinephrine /see Adrenaline/ fatty acid — polyunsaturated — microal- hypoglycaemia 828 Errata 98 buminuria 165 Eli Lilly/EASD Research Fellowship 1992 Erythrocyte — ATP release — diabetes Type 2— metabolic effects 777 Following page 1010 A 172 with exercise 340 Embryo — maternal diabetes — free radicals — glucose handling — diabetes — metformin evaluation — barcode system A 165 —rodents A 35 A 198 diabetes— Type 2 A 165 ~ — GLUT expression-rat A 35 — membrane -diabetes A 54 fat — fish oil —d iabetes Type 2 glucose - pre-implantation development — mater- - rheology — diabetes, abnormalities in — turnover A 40 nal diabetes —insulin 406 monocyte, activated, role of A 171 fa/farat A 39 Endothelial, Endothelium /see also Aorta, Eurodiab Following page 906 lipid handling, effect on A 30, A 31, Arterv/ Exercise — assessment A 164 A 31 cell — aldose reductase mRNA expres- — diabetes— Type 2-—withdiet 340 peroxidation A 40 sion — glucose, effect of 730 — energy expenditure — diabetes — Type 1 metabolic fate & obesity A 39 - — calf pulmonary artery 730 A 73 glucose transporter, effect on — rat -~ — hyperglycaemiefafe,c t of — free radi- — fuel metabolism — fructose vs. glucose A 30 calsin A 103 A72 incretin effect — diabetes —T- ype 2 — derived relaxing factor — aorta — strepto- — hyperglycaemia following — diabetes — Ty- A 31 zotocin-diabetic rat 1011 pel A73 Glucose hyperpnoea-—diabetes 425 Gastroparesis, diabetic — cisapride, effect Glucagon —intranasal 398c nerve conduction velocity, effect on 155 of A6é — secretion — catecholamine, effect of tolerance — albuminuria, reduced in — erythromycin derivative EMS23, effect A 123 A 73 of A6é — glutamate-stimulated A 123 training — glycogen synthase, effect on Gene — reg — growth factors, effect of 238 — muscarinic receptor, effect of —sub- A 91 Genetics — complications of diabetes — aldo- type A 105 — insulin sensitivity, effecton A 72, se reductase gene A 139 — neuralinfluence 1133 A 73 — diabetesS lw — sympathetic stimulation — diabetic rat — islet B-cell function A 109 mitochondrial DNA? 1181r 1035 — skeletal muscle glucose metabolism twin study— Finland 1060 — synthesis 701r A 53 Type 1 /see also HLA] Glucocorticoid — diabetogenic effect — islet Eye /see also Cataract; Retina; Retino- — familial occurrence A 25 glucose cycling A 103 pathy; Vision/ — HLA ~aetiologic fraction 475 — nocturnal — glucose homeostasis, effect — diabetic complications — European Asso- —- HLA-DQ RFLP 254 on A195 ciation for Study of(EASDEC) 190w — insulin-gene region A 137 Glucokinase — expression — liver vs. islet — vitreous oxygen tension — streptozotocin Japan 419 A 138 diabetes—Errata 98 — Erratum 906 — gene-~cDNA probe 743 manganese superoxide dismutase —~—— Erratum 1100 polymorphism A 71 — — diabetes—Type 2 632 F — T-cell receptor gene A 137 - — polymorphism-MODY A 62 — tumour necrosis factor gene A 138 ~-—- MODY A63 Family study — diabetes — Type 1 — Finland Type 2-— early onset — glucokinase mu- Gluconeogenesis — hepatic — diabetes Ty- 70 tant A 62 pe 2—substrate availability A 106 — — Type 2-plasmaamylin 291,801 — glucokinase gene A 139,632 Glucose — analogue — D-glucose - Fat /see also Adipose tissue; Diet; Obesity/ — GLUT [see also GLUT/ anomers 505 — distribution — coronary heart disease --1 A722 — autoxidation — diabetic nephropathy, role mortality 464 -~-—4 486 in 499r — — glucose tolerance and 653 — insulin receptor tyrosine kinase 486 — blood-—ageeffect A 132 — — insulinresistance 785 Mauritius 632 bimodality — genetic A 132 — — metabolic disturbances A 92 - mitochondrial gene A 139 - monitoring /see also Glucose — sensor] Fatty acid — non-esterified — adrenaline, re- skeletal-muscle glucose-utilisation — device —-SatelliteG A 204 sponse to 129 proteins A 72 sampling method — hypoglycaemia ~ — growth hormone, effect of — pulsatili- — — — South Indians A 140 287 ty 542 — heritability— diabetes 1060 — dependent insulinotropic peptide /see ~ polyunsaturated —d ietary /see also Diet- — malnutrition-related diabetes 283 GIP/ fat/ - methods — polled multiples single nucleo- — disposal - mathematical model 676 — —- diabetes 165 tide primer extension A 71 - fluxes — skeletal muscle — mathematical Fertility —diabetes—Type 2 A 133 Geriatrics /see Elderly] model A 28 Fetus — rat — cartilage proteoglycan produc- Germ theory of disease 187 — homeostasis — hepatic glucose output, ro- tion — maternal diabetes 517 GIP (glucose-dependent insulinotropic pep- leof A 106 — umbilical artery velocimetry — maternal tide) — monitoring—subcutaneous 1177 diabetes A 180 — endocrine pancreas, effects on — sulpho- — production, hepatic — amylin, effect of Finland — diabetes incidence 70 nylureasynergism A 85 116 Flow cytometry — fluorescence-activated Glomerular — charge selectivity — diabetes - — PimaIndians 753 436 A 144, A 145 — — vagotomy, effect of A7 — human fetal pancreas 436 — — glycaemic control, effectof 1165 — sensor— blood — fine-needle A 205 — light-scatter A 119 — function — C-peptide, effect of — diabe- — — immune response to A 206 Fluorescence-activated cell sorting 436 tes 121 — — microdialysis —s ubcutaneous 1177, Foot, diabetic — osteomyelitis — 111In-IgG - — diabetes — kallikrein excretion and 857 1087 scintigraphy A 159 ~ — — prostaglandin excretion and 857 noninvasive near-infra-red spectro- — transcutaneous oxygen tension A 173 — — diabetic rat —sorbinil, effect of 414 metry A 204 — ulceration —risk factors A 158, A 159 — hyperfiltration — prospective follow-up — — subcutaneous 224 — — — foot pressures 660 A 70 — — — calibrationin vivo A 205 - — treatment A 159 — mesangial cell — angiotensin II effect - - microdialysis A 205 Free radical — defence — diabetes — ascorbic glucose, effect of A 10 ~ — — self-tuning A 204 acid, effect of A 167 — — atrial natriuretic factor , effect of A 10 — — memb— barctearialn ceellul ose A 204 islet toxicity A 215 — — extracellular matrix synthesis — gluco- — subcutaneous — continuous monitoring superoxide — polymorphonuclear cell — se, effectof A 11 1087 diabetes A 10 — — — paracrine effects A 11 tolerance — birth-weight and 444 — — heparan sulphate proteogiycan — gluco- heterogeneity — genaendt anithrcopo - se, effect of 183 metric factors 653 G number — diabetes — Type | & Type 2 — — impaired— islet B-cell function A 109 844 — — — mortality 760 GAD [see Glutamic acid — decarboxylase/ select—ia svseisstmyen t —diabetes A 145 tracer — '*C-labelled — mass spectrome- gag (group-specific antigen) — protein P30 stereology 803,844 try A102 614 — structure—diabetes—Type 1 803r *H-2-deoxy-D-glucose 310 Galanin — antagonist — galantide II A 126 GLP-i (glucagon-like peptide-1) 701r - transport — hyperglycaemeifafe,c t of Gastric emptying — diabetes — cisapride — (7-36) amide -—receptor A 83 rat muscle A 80 treatment A 203 — — insulinotropic effect — basal state — — insulin-stimulated — phosphodiesterase — hyperglycaemeifaf,ec t of A5 A 109 activation in A 89 Gastric inhibitory peptide /see GIP/ — peptides—structure A 109 - skeletal muscle — amylin, effect of 26 1199 Glucosidase - transporter /seeGLUT/ — — D-lysine A55 coronary perfusion — hyperinsulinaemia brain 304 — — flavonoid A 55 A 94 - endothelium A 18 - LDL 202 - glucose transporters — phorbol ester, ef- turnover — assessment A 27 Glycogen — metabolism — adrenaline, effect fectof A 89 dawn phenomenon 372 of 399 ischaemia — silent — diabetes — autonomic diabetes—cirrhosis A 37 - placenta 45 neuropathy A 154 Type | — impaired glucose disposal — synthase — muscle — hyperglycaemia, ef- myocardium — GLUT expression — diabe- A 106 fect of —diabeticrat A 53 tes—rat A 45 Type 2 A 36 — — — Type 2diabetes A 54 — hyperglycaemia, direct effect of A 94 glucagon, roleof A 37 — — — diabetes—Type 2 80 rate variability — childhood diabetes 452 extended fasting, effect ofin man 357 — — — diabetes — Type 2 - diet, effect of size — diabetes — Type 1 — twin study hyperglycaemia, effect of — minimal 777 A 95 model analysis A 28 Glycolysis — adrenaline, effect of 399 Heat — shock protein 60 /see HSP60/ insulin, basal, role of A 36 Group-specific antigen /see gag/ Height /see Stature/ lipid metabolism and A8 Growth /see also Stature/ Heparan sulphate — proteoglycan — glome- liver—denervated A 37 — B-cell, pancreatic—diabetes 193r rular mesangial cell 183 utilisation — lipids, effects of A 7 — factor -—insulin-like /see IGF/ Hepatocyte — culture — rat - IGF-II action index 310 fetal — glucose tolerance in adult life 444 216 regulation extended fasting, effect of hormone — deficiency — dawn phenome- Heterogeneity — diabetes — South India 283 inman 357 non, absence of 372 Hexose — monophosphates — skeletal mus- Glucosidase — inhi/sbee ia-gtlucoosirdas e - deficiency — lipolysis normal in diabe- cle 399 inhibitor/ tes 372 HLA - X-diabetes—Type 1 A 71 Glucotoxicity /see Insulin — secretion — hy- GLUT-2 expression, effect on — rat — assay — serological vs. DNA — diabetes — perglycaemia/ liver A 66 Type 1 475 GLUT (glucose transporter) insulin resistance due to — route of ad- Class I — diabetes — Type 1 — Finland 2— expression — insulin & glucose, effects ministration and A 87 A 135 of A44 lipolytic effect — fasting A8& — expression —lymphocyte — diabetes — islet 1125 metabolic effects A 20 Type 1 A214 liver vs. islet A 138 - — continuous vs. pulsatile administra- — islet B-cell, expression by — mumps vi- 3 304 tion 542 rus, effect of 63 4— expression — diabetes - Type 1 —adi- — diabetes—Type 1 542 Class II -diabetes Type 1 475 pose tissue A 90 -- Type2 A&4 — — Chinese A 136 Type2 143 receptor — B-cell, pancreatic A 22 — — France A 135 Erratum 594 releasing-hormone — glucose homeo- — — glutamic acid decarboxylase anti- phosphorylation, effect of A 90 stasis, effecton? A 105 bodies 996 polymorphism —diabetes—Type 2 486 — treatment — insulin resistancei n A 66 — heterogeneity A 136, A 137 spontaneously hypertensive rat 712 islet—reggene 238 - Japan 419 subcellular distribution — diabetes 456 pericyte — glucose, effect of — retina vs. — — Erratum 906 tissue-specific — b>-adrenergic stimula- brain 818 — polyendocrinopathy A 71 tion, effect of A 53 — rate -prediabetes— Type 1 528 non-coding region — diabetes — Type | Glutamic acid —d ecarboxylase /see also An- ~— vascular smooth muscle — diabetes — rat A 136 tibody — islet-cell — antigen/ 104 diabetes — secondary failure of oral hypo- antigenicity 380 GTP binding protein — pertussis-toxin sensi- glycaemicagent 1159 expression — glucose, regulation by tive —insulin secretion A 118 DQ [see also HLA - Class II] A4l — rab3—insulin secretion A 12 — diabetes Type 1 254 insulin secretion rate and 490 - regulatable—islet A 12 — protection A 137,A 138 islet A,BandDcells A 41 Guanosine monophosphate - rat islet 1020 — Sweden A 136 twoforms A 129 Gut motility—diabetes A 6 - expression — diabetes — Type 1 —- Spain Glutamine — metabolic effects A 7 — hyperglycaemia, effect of A5 583 Glutathione — neuropathy, treatment of — islet-cell antibody and 570 streptozotocin-diabetirca t 813 — RFLP 254 Glycaemic control —c ognitive function dur- H DR - prediction of diabetes Type 1 in si- ing hypoglycaemia 828 blings 955 diabetes — Type 2 — assessment fasting Haemostasis— diabetes A 170 genotype — diabetes Type 1 -Finland 70 blood glucose A 200 — Factor VIII:C-—diabetes 863 haplotype — diabetes Type 1 — Algeria lysosomal enzymes, plasma 991 plasminogen aactivator — inhibitor A 135 microalbuminuria, effect in 1165 A 186 — —— Finland A 135 microalbuminuria and 1049 Thrombin activity — diabetes 863 islet-cell antibodies and 550 retinopathy and 1049 von Willebrand factor — diabetic retino- HMG CoA reductase inhibitor — simvasta- Glycation — advanced end-product amino- pathy 555 tin—diabetic nephropathy 447 guanidine, inhibition by 96 Handergometer 1151 — — insulin resistance unaffected A 169 end-products —-m onocyte adhesion 160 HbA, assay, rapid—desktop A 206 HSP60 (heat — shock protein 60) albumin assay HPLC 699c — rapid—immunoturbidometric A 206 — related protein — islet B-cell secretory collagen —a minoguanidine, effect of 19 dynamics — fall after return to normogly- granules 316 Vitamin E, effect of 913 caemia 191c Hyperandrogenism — insulin resistance — diabetic nephropathy, role in 499r HDL - /see Lipoprotein - HDL/ spironolactone, effect of A 86 end products, advanced 19 Heart — coronary disease — cholesterol syn- Hyperglycaemia — diabetic nephropathy, ro- fibronectin — vascular smooth muscle ad- thesis and-—diabetes A 167 lein 499r hesion A 54 - hyperinsulinaemiaan d 766 — glomerular mesangial cell, effect on 183 haemoglobin /see HbA, ./ mortality— diabetes 464 — postprandial —acarbose, effect of — neuro- inhibitor — ascorbic acid A 55 - — impaired glucose tolerance 464 pathy 325 1200